

Galapagos to hold Annual R&D Update 2017 on 20 June

Mechelen, Belgium; 17 May 2017; 7.30 CET - Galapagos NV (Euronext & NASDAQ: GLPG) announces it will hold its Annual R&D Update 2017 on 20 June at 8 AM EDT at the Yale Club in New York City. This event will also be webcast.

Each year, Galapagos presents its progress in discovering and developing therapies with novel modes of action to shareholders, investors, banks, and the media. This year's event will feature updates on selective JAK1 inhibitor filgotinib, currently in multiple Phase 2 and Phase 3 studies, and on the triple combination therapy development in cystic fibrosis. Galapagos will further highlight progress in its other partnered and proprietary programs, including earlier stage assets moving forward.

Please RSVP to susan@sanoonan.com to reserve your place at breakfast starting at 7:30 AM EDT/13.30 CET at the Yale Club, 50 Vanderbilt Ave, NY on 20 June 2017. The event also will be webcast starting at 8 AM EDT/14.00 CET, to be accessed via www.glpg.com.

About Galapagos

Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises Phase 3, Phase 2, Phase 1, pre-clinical, and discovery programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis and other indications. We have discovered and developed filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective inhibitor for inflammatory indications to patients all over the world. Galapagos is focused on the development and commercialization of novel medicines that will improve people's lives. The Galapagos group, including fee-for-service subsidiary Fidelta, has approximately 530 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia. More information at www.glpg.com.

Contacts

Investors:

Elizabeth Goodwin

VP IR & Corporate Communications

+1 781 460 1784

Media:

Evelyn Fox

Director Communications

+31 6 53 591 999

communications@glpg.com

Paul van der Horst

Director IR & Business Development

+31 6 53 725 199

ir@glpg.com

Forward-looking statements

This release may contain forward-looking statements, including statements regarding Galapagos' strategic ambitions, the anticipated timing of clinical studies with product candidates and the progress and results of such studies. Galapagos cautions the reader that forward-looking statements are not guarantees of future performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition and liquidity, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if Galapagos' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors

that may result in differences are the inherent uncertainties associated with competitive developments, clinical trial and product development activities and regulatory approval requirements (including that data from the ongoing and planned clinical research programs may not support registration or further development of product candidates due to safety, efficacy or other reasons), Galapagos' reliance on collaborations with third parties (including its collaboration partner for filgotinib, Gilead, and with its collaboration partner for cystic fibrosis, AbbVie), and estimating the commercial potential of Galapagos' product candidates. A further list and description of these risks, uncertainties and other risks can be found in Galapagos' Securities and Exchange Commission (SEC) filings and reports, including in Galapagos' most recent annual report on form 20-F filed with the SEC and subsequent filings and reports filed by Galapagos with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.